What is Synagis (palivizumab) used for?
Synagis is a brand of palivizumab, a preventive medicine used to help protect certain babies and children from serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) [1].
Who typically gets Synagis for RSV prevention?
Synagis is used only for patients who are considered at higher risk for severe RSV disease. Those groups are defined by medical and prescribing guidance and generally focus on very young infants and certain infants with specific health conditions (for example, some premature infants and some children with significant heart or lung disease) [1].
How is Synagis given, and how often?
Synagis is given as injections. Because RSV seasons vary by location, clinicians typically use a dosing schedule timed to the RSV season rather than year-round use [1].
What does Synagis do after an RSV infection starts?
Synagis is designed for prevention (reducing the chance of developing serious RSV illness). It is not an RSV vaccine and is not used as a treatment to cure an existing RSV infection [1].
What side effects do people ask about?
Commonly reported issues with antibody injections can include reactions around the injection site and other typical injection-related effects. Patients should discuss their child’s risk profile with a clinician and report any concerning symptoms after dosing [1].
How does Synagis compare with newer RSV prevention options?
RSV prevention for infants has expanded over time with additional products (including options that may be used seasonally or for other eligible risk groups). Which option a patient can receive depends on age, risk factors, timing, and local guidance [1].
Where can I verify the official prescribing details?
The most reliable source for eligibility criteria, dosing schedule, and safety information is the product label and prescribing information for Synagis (palivizumab) [1].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/ (Search for “Synagis palivizumab prescribing information” on FDA’s accessdata site.)